It hasn't been a great afternoon session for SciSparc investors, who have watched their shares sink by -10.72% to a price of $0.82. Some of you might be wondering if it's time to buy the dip. If you are considering this, make sure to check the company's fundamentals first to determine if the shares are fairly valued at today's prices.
SciSparc Ltd., a specialized clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. The company belongs to the Basic Materials sector, which has an average price to earnings (P/E) ratio of 10.03 and an average price to book (P/B) ratio of 2.08. In contrast, SciSparc has a trailing 12 month P/E ratio of -0.28 and a P/B ratio of 0.416.
SciSparc has moved -81.26% over the last year compared to -9.23% for the S&P 500 — a difference of -72.03%. SciSparc has a 52 week high of $5.0 and a 52 week low of $0.61.